Navigation Links
Pharmaceutical Consortium Selects BioFortis Software to Manage Collaborative Clinical Data and Biobanking Activities
Date:3/14/2012

COLUMBIA, Md., March 14, 2012 /PRNewswire/ -- The PML Consortium, an association of pharmaceutical and biotechnology companies, has recently selected the Labmatrix and Qiagram software environments from BioFortis to share and manage data relating to biospecimens in a collaborative effort to study a serious adverse event.

Progressive multifocal leukoencephalopathy (PML) is an often-fatal disease caused by the JC virus in immunocompromised patients. PML has been identified as a known side effect to certain immunosuppressive drugs. Several pharmaceutical and biotechnology companies have established the PML Consortium in order to pool study resources together, so they can derive insights that otherwise might not be gained from separate, individual studies. Current members of the PML Consortium include Biogen Idec, Bristol-Myers Squibb, Elan, Pfizer, and Roche.

Through the web-accessible Labmatrix and Qiagram collaborative software environments, global PML Consortium members can 1). centrally manage de-identified or anonymized patient clinical profiles and biospecimen information in the virtual sample bank, 2). explore available biospecimens in the virtual sample bank and related data using complex, ad hoc criteria, 3). request, approve, and track transfers of biospecimens in the virtual sample bank, and  4). log user interactions and virtual sample bank inventory history for usage transparency, information security, and accountability.

"This application will enable us to store clinical data and sample data collected by the Consortium, and enable research to be carried out in an innovative collaborative effort and thorough scientific approach into PML and its causes," states Sophie Banzet, M.D., Chair of the PML Consortium Board of Directors.

"With the complementary capabilities of a transactional database for managing daily scientific operations, and a graphical data exploration engine for posing complex questions," states BioFortis CEO Jian Wang, Ph.D., "our software environment is an informatics one-stop-shop for the PML Consortium researchers and collaborators."

About BioFortis, Inc.

BioFortis, Inc. provides enterprise software solutions within several key application areas including translational research, biobanking, biomarker discovery and clinical research. With the ability to centralize life sciences data sets in a tightly-linked, highly-annotated, and user-friendly manner, our solutions help customers to standardize on best practices in research data management within the biopharmaceutical industry, academia and government research institutions. BioFortis' website address is www.BioFortis.com

Labmatrix and Qiagram are registered marks of BioFortis, Inc.


'/>"/>
SOURCE BioFortis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
2. Onyx Pharmaceuticals to Present at Upcoming Investor Conferences
3. Avanir Pharmaceuticals to Participate in Citi 2012 Global Health Care Conference
4. Swedish Bactiguard to Enter Into an Exclusive Distribution Agreement With Cadila Pharmaceuticals
5. Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2011 Financial Results on Wednesday, March 7, 2012
6. BioDelivery Sciences Receives Patent Allowance Triggering $15 Million Milestone Payment from Endo Pharmaceuticals
7. Questcor Pharmaceuticals to Present at the Leerink Swann Global Healthcare Conference on February 16, 2012
8. Leading Pharmaceutical Marketing Research and Consulting Company Introduces Intelligent Efficiency Program
9. Galien Foundation Announces 2012 Awards Program For Best Biopharmaceutical Products and Best Medical Technology
10. Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims
11. MAP Pharmaceuticals Appoints W. James OShea to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... 2017 Interpace Diagnostics Group, Inc. (NASDAQ: ... clinically useful molecular diagnostic tests and pathology services, ... securities purchase agreement with three  institutional investors to ... stock in a registered direct offering.  In a ... sell to the same investors warrants to purchase ...
(Date:1/21/2017)... CAMBRIDGE, Mass. , Jan. 21, 2017   ... of novel compounds designed to target cancer stemness pathways, ... lead investigational compound, napabucasin, at the 2017 American Society ... San Francisco . In ... administered investigational agent designed to inhibit cancer stemness pathways ...
(Date:1/20/2017)... , Jan. 20, 2017 Ginkgo ... of Gen9, a pioneer in the synthesis and ... unique expertise in assembling pathway-length synthetic DNA into ... and capacity in the construction of new organism ... industries. "Gen9 was founded to significantly ...
(Date:1/19/2017)... 2017 Research and Markets has announced the ... Cancer Type, Application - Global Opportunity Analysis and Industry Forecast, 2014-2022" ... ... market is projected to reach $15,737 million by 2022 from $6,521 ... 2022. Omic technologies segment accounted for more than ...
Breaking Biology Technology:
(Date:12/12/2016)... , Dec. 12, 2016  Researchers at ... possibilities for graphene by combining the material with ... highly sensitive pressure detector able to sense pulse, ... a small spider.  The research ... can be read here:  http://science.sciencemag.org/content/354/6317/1257 ...
(Date:12/8/2016)... 8, 2016  Singulex, Inc., the leader in Next ... into a license and supply agreement with Thermo Fisher ... provides Singulex access to Thermo Scientific BRAHMS PCT (Procalcitonin), ... is used to diagnose systemic bacterial infection and sepsis ... to aid in assessing the risk of critically ill ...
(Date:12/7/2016)... , December 7, 2016 BioCatch , ... expansion of its patent portfolio, which grew to over 40 granted and ... , , ... recently filed patent entitled " System, Device, and Method Estimating ... that enables device makers to forego costly hardware components needed to estimate ...
Breaking Biology News(10 mins):